Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis

• DOI: 10.1371/journal.pone.0083892
• Publication Date: 2013-12-19T17:08:17Z
• Authors: Nino Lomtadze; Lali Kupreishvili; Archil Salakaia; Sergo Vashakidze; Lali Sharvadze; Russell R. Kempker; Matthew J. Magee; Carlos del Rio; Henry M. Blumberg
• Keywords: Hepatitis C; Hepatitis B

BackgroundThe country of Georgia has a high prevalence tuberculosis (TB) and hepatitis C virus (HCV) infection. PurposeTo determine whether HCV co-infection increases the risk incident drug-induced among patients on first-line anti-TB drug therapy. MethodsProspective cohort study; serology was obtained all study subjects at time TB diagnosis; hepatic enzyme tests (serum alanine aminotransferase [ALT] activity) were baseline monthly during treatment. ResultsAmong 326 with culture-confirmed TB, 68 (21%) co-infected, 14 (4.3%) had chronic B (HBV) infection (hepatitis surface antigen positive [HBsAg+]), 6 (1.8%) HIV co-infected. Overall, 19% developed mild to moderate hepatotoxicity. In multi-variable analysis, (adjusted Hazards Ratio [aHR]=3.2, 95% CI=1.6-6.5) found be an independent factor for Survival analysis showed that co-infected more quickly compared seronegative TB. ConclusionA in Georgia. Drug-induced hepatotoxicity significantly associated but severe (WHO grade III or IV) rare.